VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman, will present at the Cowen and Company 37 Annual Healthcare Conference in Boston, MA on March 6, 2017 at 1:20pm ET. A webcast will be available and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.

About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. The company is headquartered in Victoria, BC and focuses its development efforts globally. www.auriniapharma.com.

We Seek Safe Harbor.

View source version on businesswire.com:http://www.businesswire.com/news/home/20170302006143/en/

Aurinia Pharmaceuticals Inc.
Investor & Media Contact:
Celia Economides
Head of IR & Communications
ceconomides@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.

Released March 2, 2017

Aurinia Pharmaceuticals Inc. published this content on 02 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 March 2017 16:50:14 UTC.

Original documenthttp://ir.auriniapharma.com/press-releases/detail/74/aurinia-to-present-at-cowen-and-company-37th-annual

Public permalinkhttp://www.publicnow.com/view/C9697A939EBD41BC6735CEC04081E75F7B9AC0CE